Literature DB >> 26136883

Complete recovery from paraneoplastic anti-NMDAR encephalitis associated with a small ovarian teratoma following a laparoscopic salpingo-oophorectomy: A case report.

Kenji Imai1, Takeshi Fukuda1, Takuma Wada1, Masaru Kawanishi1, Makoto Yamauchi1, Yasunori Hashiguchi1, Tomoyuki Ichimura1, Tomoyo Yasui1, Toshiyuki Sumi1.   

Abstract

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a severe but treatment-responsive disorder, initially identified in young women with an ovarian teratoma. Symptoms include mood, behavior and personality irregularities that resemble acute psychosis. The present study reports the rare case of a patient with anti-NMDAR encephalitis and severe neurological symptoms, that exhibited a rapid recovery following a laparoscopic salpingo-oophorectomy. The 39-year-old woman was admitted to the Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine (Osaka, Japan) with a 5-day history of fever and stomach ache. One week later, the patient developed hallucinations and emotional lability. Initially, a diagnosis of limbic or herpes encephalitis was considered; thus, the patient was administered acyclovir and received steroid pulse therapy. However, the patient subsequently developed apnea, and in response, a tracheal intubation, mechanical ventilation and plasmapheresis were performed. Anti-NMDAR encephalitis was subsequently considered as a diagnosis and mediastinal and pelvic computed tomography (CT) examinations were conducted to detect for the presence of a teratoma. A 24×24-mm cystic lesion was identified in the pelvis from an abdominal CT scan and the lesion appeared to be an ovarian teratoma. In addition, serum and cerebrospinal fluid samples were collected, and were found to test positive for anti-NMDAR antibodies. A laparoscopic salpingo-oophorectomy was performed, which resulted in rapid improvement of the patients mental symptoms, followed by a complete recovery.

Entities:  

Keywords:  anti-N-methyl-D-aspartate receptor encephalitis; laparoscopic salpingo-oophorectomy; ovarian teratoma

Year:  2015        PMID: 26136883      PMCID: PMC4471776          DOI: 10.3892/etm.2015.2344

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  10 in total

1.  Reversible limbic encephalitis caused by ovarian teratoma.

Authors:  K Nokura; H Yamamoto; Y Okawara; H Koga; H Osawa; K Sakai
Journal:  Acta Neurol Scand       Date:  1997-06       Impact factor: 3.209

2.  Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab.

Authors:  H Ishiura; S Matsuda; M Higashihara; M Hasegawa; A Hida; R Hanajima; T Yamamoto; J Shimizu; J Dalmau; S Tsuji
Journal:  Neurology       Date:  2008-12-02       Impact factor: 9.910

3.  An acutely confused 15-year-old girl.

Authors:  H Okamura; N Oomori; Y Uchitomi
Journal:  Lancet       Date:  1997-08-16       Impact factor: 79.321

4.  Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.

Authors:  Josep Dalmau; Erdem Tüzün; Hai-yan Wu; Jaime Masjuan; Jeffrey E Rossi; Alfredo Voloschin; Joachim M Baehring; Haruo Shimazaki; Reiji Koide; Dale King; Warren Mason; Lauren H Sansing; Marc A Dichter; Myrna R Rosenfeld; David R Lynch
Journal:  Ann Neurol       Date:  2007-01       Impact factor: 10.422

5.  A patient with encephalitis associated with NMDA receptor antibodies.

Authors:  Lauren H Sansing; Erdem Tüzün; Melissa W Ko; Jennifer Baccon; David R Lynch; Josep Dalmau
Journal:  Nat Clin Pract Neurol       Date:  2007-05

6.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.

Authors:  Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch
Journal:  Lancet Neurol       Date:  2008-10-11       Impact factor: 44.182

7.  Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal.

Authors:  T Iizuka; F Sakai; T Ide; T Monzen; S Yoshii; M Iigaya; K Suzuki; D R Lynch; N Suzuki; T Hata; J Dalmau
Journal:  Neurology       Date:  2007-09-26       Impact factor: 9.910

8.  Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis.

Authors:  M Seki; S Suzuki; T Iizuka; T Shimizu; Y Nihei; N Suzuki; J Dalmau
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-11-21       Impact factor: 10.154

9.  Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents.

Authors:  Nicole R Florance; Rebecca L Davis; Christopher Lam; Christina Szperka; Lei Zhou; Saba Ahmad; Cynthia J Campen; Heather Moss; Nadja Peter; Amy J Gleichman; Carol A Glaser; David R Lynch; Myrna R Rosenfeld; Josep Dalmau
Journal:  Ann Neurol       Date:  2009-07       Impact factor: 10.422

10.  N-methyl-D-aspartate receptors: different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents.

Authors:  D R Lynch; N J Anegawa; T Verdoorn; D B Pritchett
Journal:  Mol Pharmacol       Date:  1994-03       Impact factor: 4.436

  10 in total
  3 in total

1.  A case of reversible anti-NMDA-receptor encephalitis: neuropsychological and neuroradiological features.

Authors:  Carlotta Mutti; Federica Barocco; Lucia Zinno; Anna Negrotti; Marco Spallazzi; Giovanni Pavesi; Simona Gardini; Paolo Caffarra
Journal:  Neurol Sci       Date:  2017-09-13       Impact factor: 3.307

2.  Rapid recovery from catastrophic paraneoplastic anti-NMDAR encephalitis secondary to an ovarian teratoma following ovarian cystectomy.

Authors:  Charuwan Tantipalakorn; Atiwat Soontornpun; Tip Pongsuvareeyakul; Theera Tongsong
Journal:  BMJ Case Rep       Date:  2016-08-10

3.  Clinical Characterization of Definite Autoimmune Limbic Encephalitis: A 30-case Series.

Authors:  Yuri Shojima; Kenya Nishioka; Masao Watanabe; Takayuki Jo; Keiko Tanaka; Hiroshi Takashima; Kazuyuki Noda; Yasuyuki Okuma; Takao Urabe; Kazumasa Yokoyama; Nobutaka Hattori
Journal:  Intern Med       Date:  2019-08-21       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.